The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03169348

Enrollment

Registered

2017-05-30

Start date

2017-11-01

Completion date

2019-09-30

Last updated

2017-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Brief summary

Autoimmune thrombocytopenic purpura is an immunological disorder characterized by increased platelet destruction due to presence of anti-platelet antibodies. Hepatitis C virus infection, which is one of the most common chronic viral infections worldwide, may cause secondary chronic immune thrombocytopenic purpura. It seemed to play a pathogenic role in autoimmune thrombocytopenic purpura. Moreover, the successful response (negative hepatitis C virus - ribonucleic acid) to tapered steroids and antiviral therapy was useful to revert thrombocytopenia

Interventions

DRUGsofosbuvir daclatasvir

oral tablets

DRUGLedipasvir/sofosbuvir

oral tablets

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Hepatitis C virus infection and thrombocytopenia before treatment

Exclusion criteria

* Infection Hepatitis B virus * Hypersplenism * Diseases affecting Bone marrow * Major clotting factors abnormalities eg. Disseminated intravascular coagulopathy, severe Prothrombin deficiency

Design outcomes

Primary

Measure	Time frame
the mean difference on the platelet count	6 month

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026